scholarly journals Percutaneous Transhepatic Biliary Interventions

2018 ◽  
Vol 02 (01) ◽  
pp. 027-037
Author(s):  
Ankusha Yadav ◽  
Naveen Condati ◽  
Amar Mukund

AbstractBiliary tract interventions remain indispensable procedures for treatment of a wide arena of biliary tract pathologies. The increased use of endoscopic retrograde cholangiopancreatography (ERCP) for biliary tract evaluation and intervention has resulted in fewer patients requiring percutaneous transhepatic biliary interventions. However, there remains a subset of patients in whom ERCP is not feasible. Interventional radiologists play an important role in the management of biliary pathologies in such patients who cannot be benefited by endoscopic means. These interventions may at times be challenging; hence, awareness of normal and variant biliary tract anatomy and the variety of biliary tract interventions make the job easy. This article reviews the role of percutaneous transhepatic interventions in the management of a variety of biliary tract diseases, both benign and malignant, general indications and contraindications, preprocedural evaluation, and technical considerations specific to indications.

Author(s):  
Mohammed Yousif Rashid ◽  
Anupa Gnawali

AbstractAcute pancreatitis is the most common iatrogenic dilemma of endoscopic retrograde cholangiopancreatography, and it is associated with significant morbidity and mortality. Several factors have been implicated in the pathogenesis of post-endoscopic retrograde cholangiopancreatography pancreatitis, and preventive measures were practiced accordingly. This study aims to refine the potential mechanisms that trigger post-endoscopic retrograde cholangiopancreatography pancreatitis and define the role of enteropeptidase in the pathogenesis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Furthermore, address the role of a new novel medication known as SCO-792, a potent enteropeptidase inhibitor, in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.Post-endoscopic retrograde cholangiopancreatography pancreatitis is caused by premature activation of the pancreatic enzymes within the pancreatic parenchyma. This activation is either an autoactivation due to direct provocation of intra-acinar enzymes as a result of the procedure or due to activation by enterpeptidase, a rate-limiting enzyme. Endoscopic retrograde cholangiopancreatography interjects duodenal juice that is rich in enterokinase into the pancreatic-biliary tract, which in turn leads to intra-ductal activation of trypsinogen and subsequent enzymes. Given the vital role of enterokinase in initiating the pathogenesis of pancreatitis, enteropeptidase inhibition may prevent and reduce the severity of post-endoscopic retrograde cholangiopancreatography pancreatitis.SCO-792, a novel enteropeptidase inhibitor, is developed by SCOHIA Pharma, and pre-clinical trials confirmed its efficacy in inhibiting enteropeptidase. Studies are needed to confirm the efficacy of enteropeptidase inhibitors in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.


2021 ◽  
Vol 6 (1) ◽  
pp. 25
Author(s):  
EmadM Abd-Elkhalik ◽  
MorsyM Morsy ◽  
SalahI Mohammed ◽  
MahmoudR Shehata ◽  
AdnanA Mohammed

Sign in / Sign up

Export Citation Format

Share Document